
- ONCOLOGY Vol 22 No 14
- Volume 22
- Issue 14
Two Orphan Drug Designations Granted for Reviroc in NHL
The biopharmaceutical company Kiadis Pharma recently announced that the US Food and Drug Administration (FDA) has granted its product Reviroc orphan drug designations for the treatment of two types of non-Hodgkin lymphoma (NHL)-one for diffuse large B-cell lymphoma and the other for the treatment of follicular lymphoma.
The biopharmaceutical company Kiadis Pharma recently announced that the US Food and Drug Administration (FDA) has granted its product Reviroc orphan drug designations for the treatment of two types of non-Hodgkin lymphoma (NHL)-one for diffuse large B-cell lymphoma and the other for the treatment of follicular lymphoma. Reviroc is under development for the elimination of cancer cells from an autologous graft in bone marrow transplantations for end-stage blood cancer patients.
Articles in this issue
almost 17 years ago
The Absent-Minded Professor: An Unusual Complication of Melanomaalmost 17 years ago
Inflammatory Breast Cancer: A Complex Diseasealmost 17 years ago
Defining the IBC Phenotypealmost 17 years ago
Acupuncturealmost 17 years ago
NDA Submitted for Trabectedin to Treat Relapsed Ovarian Canceralmost 17 years ago
FDA Considers Update for Tanning Bed Labelsalmost 17 years ago
FDA Approves New Imaging System to Enhance Cervical Cancer DetectionNewsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.



















































































